| Identification | Back Directory | [Name]
Alanine, N-[(S)-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-2-methyl-, 1-methylethyl ester | [CAS]
1571076-26-0 | [Synonyms]
HS-10234
Tenofovir amibufenamide
Alanine, N-[(S)-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-2-methyl-, 1-methylethyl ester | [Molecular Formula]
C22H31N6O5P | [MOL File]
1571076-26-0.mol | [Molecular Weight]
490.5 |
| Chemical Properties | Back Directory | [Boiling point ]
643.8±65.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
4.21±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Tenofovir amibufenamide (HS-10234), a Tenofovir prodrug, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study[1][2]. | [References]
[1] Zhihong Liu, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021 Nov;54(9):1134-1149. DOI:10.1111/apt.16611
[2] Hong Zhang, et al. Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection. Aliment Pharmacol Ther. 2021 Jan;53(2):243-252. DOI:10.1111/apt.16196 |
|
|